Fluxion Therapeutics
Biotechnology Research • 
San Diego, California, United States • 1-10 Employees
Company overview
| Headquarters | San Diego, California, United States |
| NAICS | 541714 |
| Keywords | Drug Safety, Electrophysiology, Toxicology, ML, Aidd |
| Founded | 2025 |
| Employees | 1-10 |
Key Contact at Fluxion Therapeutics
Ilya Kovalenko
CEO & Founder
About Fluxion Therapeutics
Fluxion Therapeutics, a Physiomics™ Company. We use the term Physiomics to refer to network-level descriptions of electrophysiological properties and biophysical mechanisms of cells, cell membranes, ion channels, and membrane receptors; with an emphasis on the unique dynamic, continuous, and timescale characteristics of electrophysiology and biophysics, such as changes in excitability, signaling, cellular transport, membrane composition, and others. Physiomics anticipates integrating detailed physical and physiological characterization with more integrated functional perspectives and insights drawn from other ‘omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, etc.) networks and systems-level in order to better understand these mechanisms and processes. Fluxion Therapeutics applies such Physiomics NAMs models to predict Safety&Tox risks. Additionally, we are building a pipeline of neuropsychiatric and anti-epileptic candidates.
Fluxion Therapeutics revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Fluxion Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
Fluxion Therapeutics has never raised funding before.
Germany
United Kingdom
Frequently asked questions
4.8
40,000 users
